title: [Clinical pharmacology of hydroxyurea].
abstract: Hydroxyurea, an antineoplastic drug evaluated clinically more than 30 years ago, is still the principal drug in patients with myeloproliferative syndromes. It is suggested now that it should be used as initial therapy for chronic myelogenous leukemia. Recently hydroxyurea is used in the treatment of patients with sickle cell disease. It has been shown to augment production of fetal hemoglobin and decrease the propensity of abnormal hemoglobin to polymerize and from the sickle cells in this way.
authors.affiliation: Zakładu Farmakologii, II Kliniki Chorób Wewnetrznych AM w Lodzi.
authors.forename: J
authors.initials: J
authors.lastname: Góra-Tybor
authors.forename: T
authors.initials: T
authors.lastname: Robak
mesh_terms: D000755:Anemia, Sickle Cell / Q000188:drug therapy; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality; D009196:Myeloproliferative Disorders / Q000188:drug therapy
chemical_list: D006918:Hydroxyurea
vernacular_title: Farmakologia kliniczna hydroksymocznika.